<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567303</url>
  </required_header>
  <id_info>
    <org_study_id>BP41670</org_study_id>
    <nct_id>NCT04567303</nct_id>
  </id_info>
  <brief_title>Study of RO7250284 in Participants With Neovascular Age-Related Macular Degeneration</brief_title>
  <official_title>A Two-Part, Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7250284 Following Intravitreal Administration of Unmasked Multiple Ascending Doses and Masked Sustained Delivery From the Port Delivery System in Patients With Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in-human study to investigate the safety and tolerability of RO7250284&#xD;
      administered through intravitreal (IVT) injections and via the Port Delivery System in&#xD;
      participants with neovascular age-related macular degeneration (nAMD)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">November 19, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 of the study will be an open-label multiple ascending dose study, followed by subsequent assignment to 2 groups in Part 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part 1: Visual Acuity examiner; Part 2: Participant, Investigator and Sponsor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Ocular and Systemic (Nonocular) Adverse Events</measure>
    <time_frame>Part 1: Baseline up to Week 24; Part 2: Baseline up to Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Ocular Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Part 1: Baseline up to Week 24; Part 2: Baseline up to Month 12.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Ocular Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Part 1: Baseline up to Week 24; Part 2: Baseline up to Month 12.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of RO7250284 in Blood and Aqueous Humor (AH)</measure>
    <time_frame>Part 1: Baseline up to Week 24; Part 2: Baseline up to Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration Observed (Tmax) of RO7250284 in Blood and AH</measure>
    <time_frame>Part 1: Baseline up to Week 24; Part 2: Baseline up to Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the End of a Dosing Interval before the Next Dose Administration (Ctrough) of RO7250284 in Blood and AH</measure>
    <time_frame>Part 1: Baseline up to Week 24; Part 2: Baseline up to Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of RO7250284 in Blood and AH</measure>
    <time_frame>Part 1: Baseline up to Week 24; Part 2: Baseline up to Month 36</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Part 1: Intravitreal Injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO7250284 administered in ascending dose levels through IVT injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Port Delivery System with High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO7250284 administered at a high dose through the PDS implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Port Delivery System with Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO7250284 administered at a low dose through the PDS implant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7250284</intervention_name>
    <description>Part 1: multiple ascending doses by intravitreal injection. Each participant will receive RO7250284 at a constant volume of 50 microliter in the study eye.&#xD;
Part 2: participants will be randomized to one of two dose levels of RO7250284 in the PDS implant.</description>
    <arm_group_label>Part 1: Intravitreal Injections</arm_group_label>
    <arm_group_label>Part 2: Port Delivery System with High Dose</arm_group_label>
    <arm_group_label>Part 2: Port Delivery System with Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to allow AH collection.&#xD;
&#xD;
        Ocular Inclusion Criteria for Study Eye:&#xD;
&#xD;
          -  Choroidal neovascularization (CNV) exclusively due to age-related macular&#xD;
             degeneration.&#xD;
&#xD;
          -  Anti-VEGF IVT treatment-na√Øve, or pre-treated with anti-VEGF no less than two months&#xD;
             prior to Day 1.&#xD;
&#xD;
          -  Sufficiently clear ocular media and adequate pupillary dilatation to allow for&#xD;
             analysis and grading by the central reading center of fundus photography (FP),&#xD;
             fluorescein angiography (FA), fundus autofluorescence (FAF), and spectral domain&#xD;
             optical coherence tomography (SD-OCT) images.&#xD;
&#xD;
          -  Decreased best corrected visual acuity (BCVA) attributable primarily to nAMD, with&#xD;
             BCVA letter score of 78 to 34 letters (inclusive) on early treatment diabetic&#xD;
             retinopathy study (ETDRS)-like charts at screening. In case both eyes of a participant&#xD;
             are eligible, the eye with the lower BCVA score should become the study eye.&#xD;
&#xD;
        Exclusion Criteria for Study Eye:&#xD;
&#xD;
          -  History of vitrectomy surgery, submacular surgery, other intraocular surgery, or any&#xD;
             planned surgical intervention during the study period.&#xD;
&#xD;
          -  Cataract surgery without complications within three months preceding the screening&#xD;
             visit or planned during the study period.&#xD;
&#xD;
          -  Aphakia or absence of the posterior capsule.&#xD;
&#xD;
          -  Prior macular treatment with verteporfin, external beam radiation therapy,&#xD;
             transpupillary thermotherapy, or any type of laser photocoagulation.&#xD;
&#xD;
          -  Prior treatment with IVT corticosteroids or implant (e.g., triamcinolone, ozurdex,&#xD;
             iluvien).&#xD;
&#xD;
          -  Subretinal hemorrhage &gt;50% of the total lesion area and/or involving the fovea.&#xD;
&#xD;
          -  Subfoveal fibrosis or subfoveal atrophy.&#xD;
&#xD;
          -  Retinal pigment epithelial tear involving the macula.&#xD;
&#xD;
          -  History of vitreous hemorrhage, rhegmatogenous retinal detachment, glaucoma-filtering&#xD;
             surgery, tube shunts, or microinvasive glaucoma surgery, and corneal transplant.&#xD;
&#xD;
          -  History of rhegmatogenous retinal tears or peripheral retinal breaks within three&#xD;
             months prior to the screening visit.&#xD;
&#xD;
          -  Actual or history of myopia &gt;-8 diopters.&#xD;
&#xD;
          -  Uncontrolled ocular hypertension or glaucoma (defined as IOP &gt;25 mm Hg or a cup to&#xD;
             disc ration &gt;0.8, despite treatment with antiglaucoma medication) and any such&#xD;
             condition the Investigator determines may require a glaucoma-filtering surgery during&#xD;
             a participant's participation in the study.&#xD;
&#xD;
          -  Concurrent intraocular conditions (e.g., cataract, diabetic retinopathy, epiretinal&#xD;
             membrane with traction, macular hole).&#xD;
&#xD;
        Exclusion Criteria for Fellow Eye&#xD;
&#xD;
          -  BCVA letter score using ETDRS charts of &lt; 34 letters.&#xD;
&#xD;
          -  Treatment with anti-VEGF agents within one month prior to the screening visit.&#xD;
&#xD;
        Exclusion Criteria for Either Eye&#xD;
&#xD;
          -  CNV due to causes other than nAMD, such as ocular histoplasmosis, trauma, pathological&#xD;
             myopia, angioid streaks, choroidal rupture, uveitis or central serous&#xD;
             chorioretinopathy.&#xD;
&#xD;
          -  Prior participation in a clinical trial involving anti-VEGF drugs within six months&#xD;
             prior to the screening visit, other than ranibizumab, aflibercept, or faricimab.&#xD;
&#xD;
          -  Active intraocular inflammation (grade trace or above), infectious conjunctivitis,&#xD;
             keratitis, scleritis, or endophthalmitis.&#xD;
&#xD;
          -  History of uveitis, including history of any intraocular inflammation following&#xD;
             intravitreal anti-VEGF injections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BP41670 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barnet Dulaney Perkins Eye Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Retina Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Assoc of FL</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Vitreoretinal Assoc</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Center of New Jersey</name>
      <address>
        <city>Bloomfield</city>
        <state>New Jersey</state>
        <zip>07003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina - Wills Eye Hospital</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Retina PC.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Research Center for Retina</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

